Loading..

Arbutus Biopharma Corporation (ABUS) Report Analysis

Corporate Events

Positive

Arbutus Biopharma Corporation Presents New Data...

2022-06-25 08:05:00

Arbutus Biopharma Corporation announced the presentation of new clinical and pre-clinical data from its proprietary compounds at the European ...

Neutral

Arbutus Biopharma Corporation - Special Call

2022-06-08 06:05:00

To consider and present New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress(TM) 2022 and to provide AB-836 Clinical Update

Positive

Arbutus Biopharma Corporation and Vaccitech plc...

2022-06-06 11:30:00

Arbutus Biopharma Corporation and Vaccitech plc announced the first patient dosed in a Phase 2a clinical trial. This trial will evaluate Arbut...

Neutral

Arbutus Biopharma Corporation Presents at The N...

2022-06-01 17:06:00

Arbutus Biopharma Corporation Presents at The NIRI 2022 Annual Conference, Jun-06-2022 . Venue: Boston, United States. Speakers: Lisa M. Caper...

Neutral

Arbutus Biopharma Corporation Presents at H.C. ...

2022-05-17 11:40:00

Arbutus Biopharma Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 11:30 AM. Venue: Fontainebleau Miami ...

Neutral

Arbutus Biopharma Corporation to Report Q1, 202...

2022-04-21 11:39:00

Arbutus Biopharma Corporation announced that they will report Q1, 2022 results at 7:30 AM, Eastern Standard Time on May 05, 2022

Neutral

Arbutus Biopharma Corporation, Q1 2022 Earnings...

2022-04-21 11:30:00

Arbutus Biopharma Corporation, Q1 2022 Earnings Call, May 05, 2022

Neutral

Arbutus Biopharma Corporation Presents at Drug ...

2022-04-14 17:07:00

Arbutus Biopharma Corporation Presents at Drug Discovery Chemistry Conference 2022, Apr-19-2022 10:35 AM. Speakers: Michael J. Sofia, Chief Sc...

Neutral

Cambridge Innovation Institute, LLC, Drug Disco...

2022-04-14 12:01:00

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022.

Neutral

Arbutus Biopharma Corporation - Shareholder/Ana...

2022-04-11 20:06:00

AGM

Neutral

Arbutus Biopharma Corporation, Annual General M...

2022-04-11 20:06:00

Arbutus Biopharma Corporation, Annual General Meeting, May 25, 2022, at 10:00 Eastern Daylight. Agenda: To consider election of directors; to ...

Neutral

Arbutus Biopharma Corporation Presents at H.C. ...

2022-03-30 21:14:00

Arbutus Biopharma Corporation Presents at H.C. Wainwright Annual Global Life Sciences Conference, May-23-2022 .

Neutral

Arbutus Biopharma Corporation Presents at 2022 ...

2022-03-30 21:14:00

Arbutus Biopharma Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 03:00 PM. Venue: Marriott Marquis, New York...

Neutral

Arbutus Biopharma Corporation Presents at The J...

2022-03-30 21:14:00

Arbutus Biopharma Corporation Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 09:00 AM. Venue: Lotte New York Palace...

Neutral

The European Association for the Study of the L...

2022-03-30 21:14:00

The European Association for the Study of the Liver, The International Liver Congress 2022, Jun 22, 2022 through Jun 25, 2022. Venue: London, ...

Neutral

Arbutus Biopharma Corporation Presents at The I...

2022-03-30 21:14:00

Arbutus Biopharma Corporation Presents at The International Liver Congress 2022, Jun-25-2022 . Venue: London, United Kingdom.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

JMP Securities LLC, the JMP Securities Life Sci...

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Mad...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Ann...

2022-02-14 20:39:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Annual Global Life Sciences Conference, May 23, 2022 through May 25, 2022.

Neutral

National Investor Relations Institute, the NIRI...

2022-01-31 22:05:00

National Investor Relations Institute, The NIRI 2022 Annual Conference, Jun 06, 2022. Venue: Boston, United States.

Positive

Antios Therapeutics and Arbutus Biopharma Annou...

2021-12-14 12:30:00

Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced that the first patient has been dosed in a triple combination treatment ...

Neutral

Arbutus Biopharma Corporation and Qilu Pharmace...

2021-12-13 12:30:00

Arbutus Biopharma Corporation and Qilu Pharmaceutical announced that the companies have entered into an exclusive licensing agreement and stra...

Positive

Arbutus Biopharma Corporation announced that it...

2021-12-13 00:00:00

Arbutus Biopharma Corporation announced that a private placement of $15,000,000 in common shares at a price of $4.19 per share from Qilu Pharm...

Positive

Arbutus Biopharma Corporation Identifies Severa...

2021-12-07 12:31:00

Arbutus Biopharma Corporation, X-Chem Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced that Arbutus Biopharma has identified...

Positive

Arbutus Biopharma Corporation Announces Prelimi...

2021-12-01 17:51:00

Arbutus Biopharma Corporation announced preliminary data from its on-going Phase 1a/1b clinical trial demonstrating that its next generation c...

Negative

Arbutus Biopharma Corporation Appoints Tram Tra...

2021-11-11 12:30:00

Arbutus Biopharma Corporation announced that Tram Tran, M.D. has been appointed to the Arbutus Board of Directors effective immediately. Dr. T...

Positive

Arbutus Announces New Data on AB-729 in Late Br...

2021-11-10 21:30:00

Arbutus Biopharma Corporation announced new AB-729 safety and efficacy data, as well as long-term data from HBV patients following discontinua...

Neutral

Arbutus Biopharma Corporation Presents at 12th ...

2021-11-10 12:30:00

Arbutus Biopharma Corporation Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United King...

Neutral

Arbutus Biopharma Corporation has filed a Shelf...

2021-11-04 00:00:00

Arbutus Biopharma Corporation has filed a Shelf Registration in the amount of $401.019509 million. Security Name: Common Shares Security...

Neutral

Arbutus Biopharma Corporation, Q3 2021 Earnings...

2021-10-21 11:30:00

Arbutus Biopharma Corporation, Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Arbutus Biopharma Corporation to Report Q3, 202...

2021-10-21 11:30:00

Arbutus Biopharma Corporation announced that they will report Q3, 2021 results at 7:30 AM, Eastern Standard Time on Nov 04, 2021

Neutral

Arbutus Biopharma Corporation Presents at Chard...

2021-09-28 11:30:00

Arbutus Biopharma Corporation Presents at Chardan's 5th Annual Genetic Medicines Conference, Oct-05-2021 04:30 PM. Speakers: David C. Hastings...

Neutral

Arbutus Biopharma Corporation Presents at H.C. ...

2021-09-28 11:30:00

Arbutus Biopharma Corporation Presents at H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct-13-2021 01:00 PM. Speakers: Davi...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright 2nd...

2021-09-27 20:20:00

H.C. Wainwright & Co., LLC, H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct 13, 2021.

Negative

Arbutus Biopharma Corporation Appoints Lisa M. ...

2021-09-21 11:30:00

Arbutus Biopharma Corporation announced the company has appointed Lisa M. Caperelli to the newly created position of Vice President of Investo...

Neutral

Arbutus Biopharma Corporation Presents at Canto...

2021-09-07 12:08:00

Arbutus Biopharma Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 08:40 AM. Venue: New York, United States. Spea...

Neutral

Arbutus Biopharma Corporation Presents at Baird...

2021-08-26 17:20:00

Arbutus Biopharma Corporation Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 02:35 PM. Speakers: David C. Hastings, CFO & Ch...

Neutral

Chardan Capital Markets, LLC, Chardan's 5th Ann...

2021-08-24 14:20:00

Chardan Capital Markets, LLC, Chardan's 5th Annual Genetic Medicines Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

Arbutus Biopharma Corporation has filed a Shelf...

2021-08-05 00:00:00

Arbutus Biopharma Corporation has filed a Shelf Registration in the amount of $27.36 million. Security Name: Common Shares Securities Offe...

Neutral

Arbutus Biopharma Corporation Presents at 12th ...

2021-08-03 12:00:00

Arbutus Biopharma Corporation Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 04:05 PM. Speakers: David C. ...

Neutral

Arbutus Biopharma Corporation, Q2 2021 Earnings...

2021-07-29 12:00:00

Arbutus Biopharma Corporation, Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Arbutus Biopharma Corporation to Report Q2, 202...

2021-07-29 12:00:00

Arbutus Biopharma Corporation announced that they will report Q2, 2021 results at 7:30 AM, US Eastern Standard Time on Aug 05, 2021

Positive

Arbutus Biopharma Corporation Receives Authoriz...

2021-07-07 11:00:00

Arbutus Biopharma Corporation announced it has received authorization from the U.S. Food and Drug Administration to proceed with its Investiga...

Positive

Arbutus Biopharma and Vaccitech Announce Clinic...

2021-07-06 11:00:00

Arbutus Biopharma Corporation and Vaccitech plc announced that the companies have entered into a clinical trial collaboration agreement to eva...

Neutral

Wedbush Securities Inc., 12th Annual Wedbush Pa...

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Positive

Antios Therapeutics, Inc. and Arbutus Biopharma...

2021-06-29 11:00:00

Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced that the companies have entered into a clinical collaboration agreement ...

Positive

Arbutus Biopharma Corporation Presents New Data on AB-729, Ab-836 and AB-101 At the EASL International Liver Congress™ 2022 and Provides Ab-836 Clinical Update

2022-06-25 08:05:00

Arbutus Biopharma Corporation announced the presentation of new clinical and pre-clinical data from its proprietary compounds at the European Association for the Study of the Liver (EASL) International Liver Congress™ (ILC). The new clinical data for AB-729, the company's RNAi therapeutic, continues to support its development as a potential cornerstone agent for the treatment of chronic hepatitis B (cHBV) infection. In addition, when AB-729 and nucleos(t)ide analogues (NA) were discontinued in the first five patients who met stopping criteria and consented, there was no evidence of virologic or clinical relapse in at least 8-24 weeks of follow-up, which may lead to a functional cure. AB-836, oral capsid inhibitor, demonstrated robust antiviral activity, however, two patients in the 200 mg cohort experienced alanine aminotransferase (ALT) elevations. Based on these observations along with potentially correlated immunological findings, the company plans to conduct a Phase 1 clinical trial in healthy volunteers before progressing this program. William Collier, President and Chief Executive Officer of Arbutus, commented, “Our comprehensive AB-729 data package that has been accepted for presentation at EASL, is indicative of the continued impressive clinical safety and efficacy profile seen with AB-729 in 41 patients. The company's clinical team has conducted a thorough evaluation of this compound in cHBV patients with different characteristics to identify an adequate dose and dosing schedule to move into ongoing Phase 2a clinical trials which will support Phase 2b clinical program. The company believes that AB-729 is capable of being a cornerstone agent in the treatment regimen to provide a functional cure for patients with cHBV.” AB-729-001 Clinical Data Poster Presentations. Professor Man-Fung Yuen, D.Sc., M.D., Ph.D., Deputy Head of Department, Chief of Division of Gastroenterology and Hepatology, Master of Lap Chee, University of Hong Kong, and lead investigator of AB-729-001 clinical trial, presented a poster titled, “Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729”. This presentation focused on the preliminary safety and virology data from those patients in part 3 of the AB-729-001 clinical trial who completed treatment with AB-729 and, after meeting the protocol-defined criteria, elected to stop their NA-therapy (n=9). Prof. Yuen reported on the first five of the nine patients that had between 8 and 24 weeks of data following discontinuation of all treatment. The mean HBsAg for the five patients at baseline was 2887 IU/mL (range 1392-6765) compared to 69 IU/mL (range 4.58-150.1) at the last visit after discontinuing all treatment. All five patients remain off all treatment, and all have HBsAg levels below pre-baseline levels. None of the patients have met clinical or virologic relapse criteria. There were no adverse events (AEs) reported, no ALT elevations observed, and HBV DNA levels remain either less than the LLOQ (lower limit of quantification) or have transiently risen and subsequently decreased without intervention.

Neutral

Arbutus Biopharma Corporation - Special Call

2022-06-08 06:05:00

To consider and present New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress(TM) 2022 and to provide AB-836 Clinical Update

Positive

Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

2022-06-06 11:30:00

Arbutus Biopharma Corporation and Vaccitech plc announced the first patient dosed in a Phase 2a clinical trial. This trial will evaluate Arbutus’ RNAi therapeutic candidate, AB-729, in combination with Vaccitech’s T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NA) therapy for the treatment of patients with virologically-suppressed chronic HBV infection (cHBV). The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients. The trial is designed to enroll 40 cHBV patients. All patients will receive AB-729 (60mg every 8 weeks) plus NA therapy for 24 weeks. At week 24, treatment with AB-729 will stop. Patients will continue only their NA therapy and will be randomized to receive either VTP-300 or placebo for an additional 24 weeks. At week 48 all participants will be evaluated for eligibility to either discontinue or remain on NA therapy.

Neutral

Arbutus Biopharma Corporation Presents at The NIRI 2022 Annual Conference, Jun-06-2022

2022-06-01 17:06:00

Arbutus Biopharma Corporation Presents at The NIRI 2022 Annual Conference, Jun-06-2022 . Venue: Boston, United States. Speakers: Lisa M. Caperelli, Vice President of Investor Relations.

Neutral

Arbutus Biopharma Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 11:30 AM

2022-05-17 11:40:00

Arbutus Biopharma Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 11:30 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: William T. Symonds, Chairman of Scientific Advisory Board.

Neutral

Arbutus Biopharma Corporation to Report Q1, 2022 Results on May 05, 2022

2022-04-21 11:39:00

Arbutus Biopharma Corporation announced that they will report Q1, 2022 results at 7:30 AM, Eastern Standard Time on May 05, 2022

Neutral

Arbutus Biopharma Corporation, Q1 2022 Earnings Call, May 05, 2022

2022-04-21 11:30:00

Arbutus Biopharma Corporation, Q1 2022 Earnings Call, May 05, 2022

Neutral

Arbutus Biopharma Corporation Presents at Drug Discovery Chemistry Conference 2022, Apr-19-2022 10:35 AM

2022-04-14 17:07:00

Arbutus Biopharma Corporation Presents at Drug Discovery Chemistry Conference 2022, Apr-19-2022 10:35 AM. Speakers: Michael J. Sofia, Chief Scientific Officer.

Neutral

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022

2022-04-14 12:01:00

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022.

Neutral

Arbutus Biopharma Corporation - Shareholder/Analyst Call

2022-04-11 20:06:00

AGM

Neutral

Arbutus Biopharma Corporation, Annual General Meeting, May 25, 2022

2022-04-11 20:06:00

Arbutus Biopharma Corporation, Annual General Meeting, May 25, 2022, at 10:00 Eastern Daylight. Agenda: To consider election of directors; to consider approval of an amendment to the arbutus biopharma corporation 2016 omnibus share and incentive plan; to consider advisory vote to approve the compensation of our named executive officers; to consider ratification of the appointment of the independent registered public accounting firm; and to consider other matters.

Neutral

Arbutus Biopharma Corporation Presents at H.C. Wainwright Annual Global Life Sciences Conference, May-23-2022

2022-03-30 21:14:00

Arbutus Biopharma Corporation Presents at H.C. Wainwright Annual Global Life Sciences Conference, May-23-2022 .

Neutral

Arbutus Biopharma Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 03:00 PM

2022-03-30 21:14:00

Arbutus Biopharma Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 03:00 PM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Gaston Picchio, Chief Development Officer, Michael J. McElhaugh, Chief Business Officer.

Neutral

Arbutus Biopharma Corporation Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 09:00 AM

2022-03-30 21:14:00

Arbutus Biopharma Corporation Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 09:00 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States. Speakers: David C. Hastings, CFO & Chief Accounting Officer, Gaston Picchio, Chief Development Officer, Michael J. McElhaugh, Chief Business Officer, Michael J. Sofia, Chief Scientific Officer.

Neutral

The European Association for the Study of the Liver, the International Liver Congress 2022, Jun 22, 2022 through Jun 25, 2022

2022-03-30 21:14:00

The European Association for the Study of the Liver, The International Liver Congress 2022, Jun 22, 2022 through Jun 25, 2022. Venue: London, United Kingdom.

Neutral

Arbutus Biopharma Corporation Presents at The International Liver Congress 2022, Jun-25-2022

2022-03-30 21:14:00

Arbutus Biopharma Corporation Presents at The International Liver Congress 2022, Jun-25-2022 . Venue: London, United Kingdom.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Annual Global Life Sciences Conference, May 23, 2022 through May 25, 2022

2022-02-14 20:39:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Annual Global Life Sciences Conference, May 23, 2022 through May 25, 2022.

Neutral

National Investor Relations Institute, the NIRI 2022 Annual Conference, Jun 06, 2022

2022-01-31 22:05:00

National Investor Relations Institute, The NIRI 2022 Annual Conference, Jun 06, 2022. Venue: Boston, United States.

Positive

Antios Therapeutics and Arbutus Biopharma Announces First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

2021-12-14 12:30:00

Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a SAVE-1 (Sustained Anti-Viral Efficacy) clinical trial will evaluate a triple combination of Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, and tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor. The multi-center, double-blind, combination clinical trial plans to enroll 40 patients including a cohort of 10 patients with chronic HBV infection assigned 8:2 to active drugs (ATI-2173+AB-729) or matching placebos. The active drugs (ATI-2173+AB-729) or placebos will be administered in combination with 300 mg of tenofovir disoproxil fumarate. ATI-2173 and tenofovir disoproxil fumarate will be administered orally and by injections once daily for 90 days. AB-729 will be administered by subcutaneous injection at Day 28 and Day 90. Following this 90-day treatment period, patients will be followed-up for safety and sustained antiviral responses for six additional months. ATI-2173 is the only ASPIN in clinical development and pre-clinical data to date for ATI-2173, alone or combined with TDF, indicate the potential for sustained HBV DNA suppression off treatment, unique among approved nucleos(t)ides and investigational anti-HBV therapies. AB-729 is an RNAi therapeutic that inhibits viral replication and reduces all HBV antigens. In clinical trials to date, AB-729 has demonstrated positive safety and tolerability data as well as meaningful reductions in HBV surface antigen.

Neutral

Arbutus Biopharma Corporation and Qilu Pharmaceutical Enters Into Exclusive Licensing Agreement and Strategic Partnership

2021-12-13 12:30:00

Arbutus Biopharma Corporation and Qilu Pharmaceutical announced that the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. AB-729 is Arbutus’s lead RNA interference (RNAi) therapeutic that is currently in multiple Phase 2a proof-of-concept clinical trials designed to evaluate it in combination with other approved or investigational agents. Under the terms of the agreement, Arbutus will receive a $40 million upfront payment and will be entitled to additional payments of up to $245 million upon reaching certain development, regulatory and sales milestones. The above amounts are net of withholding taxes. Qilu will be responsible for funding all development and commercialization activities for mainland China, Hong Kong, Macau and Taiwan. Arbutus is also entitled to receive double-digit tiered royalties up to the low 20% on annual net sales. In addition, Qilu will make a $15 million equity investment in Arbutus common shares at a price of $4.19 per share, a 15% premium of Arbutus’ previous 30-day average closing stock price calculated from December 10, 2021. The common shares to be sold in the private placement have been offered only to certain institutional and/or accredited investors in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The common shares have not been registered under the Securities Act or any state or other securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements of the Securities Act and applicable state securities laws. The Securities and Exchange Commission has not passed upon the merits of or given its approval to the common shares, the terms of the private placement or the accuracy or completeness of any private placement materials. The common shares sold in the private placement are subject to legal restrictions on transfer. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification or otherwise under the securities laws of any such state or jurisdiction. About AB-729: AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using Arbutus’ novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery. Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA. About HBV: Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection represents a significant unmet medical need. The World Health Organization estimates that over 250 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2 million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options.

Positive

Arbutus Biopharma Corporation announced that it expects to receive $14.999999 million in funding from Qilu Pharmaceutical Co., Ltd.

2021-12-13 00:00:00

Arbutus Biopharma Corporation announced that a private placement of $15,000,000 in common shares at a price of $4.19 per share from Qilu Pharmaceutical Co., Ltd. on December 13, 2021. The common shares sold in the private placement are subject to legal restrictions on transfer.

Positive

Arbutus Biopharma Corporation Identifies Several Unique Compound Series that Inhibit the SARS-CoV-2 nsp5 Main Protease

2021-12-07 12:31:00

Arbutus Biopharma Corporation, X-Chem Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced that Arbutus Biopharma has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks. Upon achievement of this milestone, as part of their discovery and research agreement, Arbutus has obtained a worldwide exclusive license to the identified molecules. The parties will continue to accelerate the development of pan-coronavirus agents to treat COVID-19 and potential future coronavirus outbreaks. In connection with achievement of this development milestone, Arbutus obtained a worldwide exclusive license to the identified small molecule inhibitors. In exchange for that license, Arbutus shall make a milestone payment to X-Chem and Proteros.

Positive

Arbutus Biopharma Corporation Announces Preliminary Data from its On-Going Phase 1A/1B Clinical Trial Demonstrating That its Next Generation Capsid Inhibitor, AB-836

2021-12-01 17:51:00

Arbutus Biopharma Corporation announced preliminary data from its on-going Phase 1a/1b clinical trial demonstrating that its next generation capsid inhibitor, AB-836, is generally safe and well-tolerated in both healthy subjects and patients with cHBV and provides robust antiviral activity. Gaston Picchio, Ph.D., Chief Development Officer at Arbutus, commented, These preliminary results demonstrate that AB-836 is generally safe and well-tolerated in both single- and multiple-doses in healthy subjects and at doses up to 100mg administered once daily for 28 days in cHBV patients. In addition, the mean Day 28 drop in HBV DNA observed to date with a relatively low dose suggests that AB-836 is a very potent inhibitor of HBV replication making it an ideal candidate to potentially completely suppress viral replication. The Phase 1a/1b clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple doses of AB-836 in healthy subjects and patients with cHBV. The trial consists of three parts. Part 1 evaluated alternating single doses of AB-836 or placebo ranging from 10mg to 175mg in a fasted or fed state in healthy subjects. Part 2 evaluated multiple ascending doses of 50mg, 100mg or 150mg of AB-836 or placebo once daily for 10 days in healthy volunteers. Part 3, which is still on-going, is currently randomizing HBV DNA positive cHBV patients who are HBeAg positive or negative to receive either 50mg or 100mg of AB-836 or placebo once daily for 28 days. In Parts 1 and 2, a total of 47 healthy subjects were enrolled and dosed. There were no deaths or serious adverse events (SAEs) observed. One healthy subject that received 50mg once daily discontinued after treatment on day 13 due to an adverse event (AE) of agitation. All but three AEs were mild (Grade 2 headache, agitation and bronchitis), and only one was assessed as related to AB-836 (Grade 1 rash). There were no clinically significant abnormalities in clinical laboratory tests, ECGs, vital signs or physical exams noted. In Part 3, 16 cHBV patients have been dosed thus far with enrollment continuing. Among those who received 100mg once daily for the full 28 days (n=4), robust antiviral activity was observed at Day 28 of treatment with a mean (SE) log change from baseline of -3.1 (0.5). There have been no deaths or AEs. One cHBV patient that received 100mg of AB-836 had a transient increase in ALT from baseline Grade 1 to Grade 3 at a single visit that resolved with continued dosing and had no associated symptoms. There were no clinically significant abnormalities in ECGs, vital signs or physical exams noted. Arbutus is continuing to enroll and dose cHBV patients in Part 3 of the clinical trial and anticipates presenting additional data at a medical conference in 2022. About AB-836; AB-836 is a next generation oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. The current standard-of-care therapy for HBV is primarily nucleos(t)ide analogues that inhibit the viral polymerase and significantly reduce, but do not eliminate viral replication. AB-836 in combination with nucleos(t)ide analogues is designed to completely eliminate viral replication in infected cells by preventing the assembly of functional viral capsids. In addition, AB-836 has been shown to inhibit the replenishment of covalently closed circular DNA (cccDNA), the viral genetic reservoir which the virus needs to replicate itself.

Negative

Arbutus Biopharma Corporation Appoints Tram Tran, M.D. to its Board of Directors

2021-11-11 12:30:00

Arbutus Biopharma Corporation announced that Tram Tran, M.D. has been appointed to the Arbutus Board of Directors effective immediately. Dr. Tran is a renowned liver and viral specialist with over 20 years of academic and industry experience as a physician scientist. Dr. Tran currently serves as Chief Medical Officer at Glympse, a biotech company focused on optimizing disease diagnosis and monitoring. Previously, she worked at Gilead Sciences as the Vice President of Medical Affairs, Global Head, Liver Diseases, Fibrosis and COVID-19. Prior to her work at Gilead, Dr. Tran was the Medical Director of Liver Transplantation, GI Fellowship Program Director at Cedars-Sinai Medical Center, and a Professor of Medicine at the Geffen School of Medicine at the University of California, Los Angeles (UCLA). She has authored and co-authored over 150 abstracts, published manuscripts and book chapters, and has been extensively involved in clinical trials and National Institutes of Health (NIH) funded research. Dr. Tran earned her undergraduate degree at UCLA, received her medical degree (M.D.) from New York Medical College, continued her training in internal medicine at Cedars Sinai Medical Center, and completed Gastroenterology and Transplant Hepatology fellowships at UCLA, where she maintains clinical and teaching activities.

Positive

Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation At AASLD

2021-11-10 21:30:00

Arbutus Biopharma Corporation announced new AB-729 safety and efficacy data, as well as long-term data from HBV patients following discontinuation of treatment with AB-729. The data are from part 3 of the Company’s ongoing Phase 1a/1b clinical trial with 60 mg or 90 mg of AB-729 dosed every four, eight or 12 weeks. The data will be presented at AASLD in a poster entitled, “Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy”. Data from the poster presentation include long-term follow-up data for patients in cohort E (60 mg every four weeks) and cohort F (60 mg every eight weeks) who had been off AB-729 treatment for six months. Suppression of HBsAg to levels <100 IU/mL were maintained up to 24 weeks off-treatment in 3 of 7 patients in cohort E and 1 of 3 patients with available data in cohort F. Patients who remain below this clinically relevant threshold for six months after stopping AB-729 treatment could consider discontinuing their nucleos(t)ide analogue (“NA”) therapy to assess the potential for functional cure. Repeat dosing of both the 60 mg and 90 mg doses of AB-729 continues to be generally safe and well- tolerated. There were no treatment related serious adverse events or discontinuations. The most common treatment emergent adverse events were injection site related of which all were grade one and did not appear to be dose or interval dependent. ALT and AST elevations were asymptomatic and not considered adverse events by the study investigators. Gaston Picchio, Ph.D., Chief Development Officer at Arbutus, commented, “AB-729 consistently delivers impressive efficacy and safety data at both the 60 mg and 90 mg doses at all dosing intervals. AB-729 represents a therapeutic option with a consistent profile that can suppress HBsAg and has the potential to be a cornerstone agent in combination with other agents to cure HBV. I look forward to continuing to evaluate AB-729 in future clinical trials.” A total of 34 patients were enrolled in cohorts E, F, G, I, and J, all of which met the eligibility criteria (>0.5 log10 HBsAg reduction at week 20) to participate in the treatment extension and 33 of which agreed to continue treatment. HBV DNA negative patients on stable NA therapy were enrolled in part 3 of this trial to receive 60 mg of AB-729 every 4 weeks (cohort E) or 8 weeks (cohort F) or 90 mg of AB-729 every 8 weeks (cohort I) or 12 weeks (cohort J). HBV DNA positive patients received 90 mg of AB-729 every 8 weeks in addition to current standard of care treatment, tenofovir disoproxil fumarate (cohort G). HBV DNA negative/HBeAg positive patients are continuing to be dosed with 90 mg of AB-729 every 8 weeks (cohort K).

Neutral

Arbutus Biopharma Corporation Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-10 12:30:00

Arbutus Biopharma Corporation Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: David C. Hastings, CFO & Chief Accounting Officer, Gaston Picchio, Chief Development Officer, Michael J. Sofia, Chief Scientific Officer.

Neutral

Arbutus Biopharma Corporation has filed a Shelf Registration in the amount of $401.019509 million.

2021-11-04 00:00:00

Arbutus Biopharma Corporation has filed a Shelf Registration in the amount of $401.019509 million. Security Name: Common Shares Security Name: Preferred Shares Security Name: Warrants Security Name: Debt Securities Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Neutral

Arbutus Biopharma Corporation, Q3 2021 Earnings Call, Nov 04, 2021

2021-10-21 11:30:00

Arbutus Biopharma Corporation, Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Arbutus Biopharma Corporation to Report Q3, 2021 Results on Nov 04, 2021

2021-10-21 11:30:00

Arbutus Biopharma Corporation announced that they will report Q3, 2021 results at 7:30 AM, Eastern Standard Time on Nov 04, 2021

Neutral

Arbutus Biopharma Corporation Presents at Chardan's 5th Annual Genetic Medicines Conference, Oct-05-2021 04:30 PM

2021-09-28 11:30:00

Arbutus Biopharma Corporation Presents at Chardan's 5th Annual Genetic Medicines Conference, Oct-05-2021 04:30 PM. Speakers: David C. Hastings, CFO & Chief Accounting Officer, Gaston Picchio, Chief Development Officer, Michael J. Sofia, Chief Scientific Officer, William H. Collier, President, CEO & Director.

Neutral

Arbutus Biopharma Corporation Presents at H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct-13-2021 01:00 PM

2021-09-28 11:30:00

Arbutus Biopharma Corporation Presents at H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct-13-2021 01:00 PM. Speakers: David C. Hastings, CFO & Chief Accounting Officer, Gaston Picchio, Chief Development Officer, Michael J. Sofia, Chief Scientific Officer, William H. Collier, President, CEO & Director.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct 13, 2021

2021-09-27 20:20:00

H.C. Wainwright & Co., LLC, H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference, Oct 13, 2021.

Negative

Arbutus Biopharma Corporation Appoints Lisa M. Caperelli as Vice President, Investor Relations

2021-09-21 11:30:00

Arbutus Biopharma Corporation announced the company has appointed Lisa M. Caperelli to the newly created position of Vice President of Investor Relations, leading investor relations strategy and communications activities, reporting to David Hastings, Arbutus’ Chief Financial Officer. Ms. Caperelli has 20 years of demonstrated experience in leading the strategy and execution of comprehensive investor relations and corporate communications programs for various early- to commercial-stage publicly traded biotechnology companies. Most recently she held the position of Associate Vice President at Harmony Biosciences. Prior to Harmony, Lisa held roles of increasing responsibility in investor relations, corporate communications and patient advocacy with several biotech companies including Marinus Pharmaceuticals, Advaxis Inc., PolyMedix and Windtree Therapeutics Inc.

Neutral

Arbutus Biopharma Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 08:40 AM

2021-09-07 12:08:00

Arbutus Biopharma Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 08:40 AM. Venue: New York, United States. Speakers: William H. Collier, President, CEO & Director.

Neutral

Arbutus Biopharma Corporation Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 02:35 PM

2021-08-26 17:20:00

Arbutus Biopharma Corporation Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 02:35 PM. Speakers: David C. Hastings, CFO & Chief Accounting Officer, Gaston Picchio, Chief Development Officer, William H. Collier, President, CEO & Director.

Neutral

Chardan Capital Markets, LLC, Chardan's 5th Annual Genetic Medicines Conference, Oct 04, 2021 through Oct 05, 2021

2021-08-24 14:20:00

Chardan Capital Markets, LLC, Chardan's 5th Annual Genetic Medicines Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

Arbutus Biopharma Corporation has filed a Shelf Registration in the amount of $27.36 million.

2021-08-05 00:00:00

Arbutus Biopharma Corporation has filed a Shelf Registration in the amount of $27.36 million. Security Name: Common Shares Securities Offered: 9,000,000 Transaction Features: ESOP Related Offering

Neutral

Arbutus Biopharma Corporation Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 04:05 PM

2021-08-03 12:00:00

Arbutus Biopharma Corporation Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 04:05 PM. Speakers: David C. Hastings, CFO & Chief Accounting Officer, Gaston Picchio, Chief Development Officer, Michael J. Sofia, Chief Scientific Officer, William H. Collier, President, CEO & Director.

Neutral

Arbutus Biopharma Corporation, Q2 2021 Earnings Call, Aug 05, 2021

2021-07-29 12:00:00

Arbutus Biopharma Corporation, Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Arbutus Biopharma Corporation to Report Q2, 2021 Results on Aug 05, 2021

2021-07-29 12:00:00

Arbutus Biopharma Corporation announced that they will report Q2, 2021 results at 7:30 AM, US Eastern Standard Time on Aug 05, 2021

Positive

Arbutus Biopharma Corporation Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, Its Proprietary Subcutaneously-Delivered RNAi Agent

2021-07-07 11:00:00

Arbutus Biopharma Corporation announced it has received authorization from the U.S. Food and Drug Administration to proceed with its Investigational New Drug (IND) application for AB-729 in a Phase 2a clinical trial. The Phase 2a proof-of-concept clinical trial will evaluate the safety and efficacy of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNa-2a in subjects with CHB. This is a randomized, open label, multicenter Phase 2a trial investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNa-2a in subjects with CHB. Pending protocol finalization, the trial is expected to enroll 40 stably NA-suppressed, HBeAg negative, non-cirrhotic CHB subjects. After a 24-week dosing period of AB-729 (60 mg SC every 8 weeks (Q8W)), subjects will be randomized into one of 4 groups: A1: AB-729 + NA + weekly Peg-IFNa-2a for 24 weeks (N = 12); A2: NA + weekly Peg-IFNa-2a for 24 weeks (N = 12); B1: AB-729 + NA + weekly Peg-IFNa-2a for 12 weeks (N = 8); B2: NA + weekly Peg-IFNa-2a for 12 weeks (N = 8). After completion of the assigned Peg-IFNa-2a treatment period, all subjects will remain on NA therapy for the initial 24-week follow up period, and then will discontinue NA treatment if treatment stopping criteria are met. If subjects stop NA therapy, they will enter an intensive follow-up period for 48 weeks.

Positive

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement

2021-07-06 11:00:00

Arbutus Biopharma Corporation and Vaccitech plc announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus (HBV) infection (CHB) who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy. The multi-center, Phase 2a clinical trial will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of Arbutus’s proprietary GalNAc delivered RNAi therapeutic, AB-729, followed by Vaccitech’s proprietary immunotherapeutic, VTP-300, in NrtI-suppressed subjects with CHB. The Phase 2a clinical trial is expected to initiate in the second half of this year and will be managed by Arbutus, subject to oversight by a joint development committee comprised of representatives from Arbutus and Vaccitech. The parties retain full rights to their respective product candidates and will split all costs associated with the clinical trial. Pursuant to the agreement, the parties intend to undertake a larger Phase 2b clinical trial depending on the results of the initial Phase 2a clinical trial.

Neutral

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Positive

Antios Therapeutics, Inc. and Arbutus Biopharma Corporation Announce Clinical Collaboration Agreement to Evaluate Ab-729 in Combination with Ati-2173 in Subjects with Chronic Hepatitis B Virus Infection

2021-06-29 11:00:00

Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, and Viread (tenofovir disoproxil fumarate), for the treatment of subjects with chronic hepatitis B virus (HBV) infection. ATI-2173, AB-729 and Viread will be evaluated in combination in a single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial. The multi-center, double-blinded, placebo-controlled, multiple-dose cohort will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of the combination of ATI-2173, AB-729 and Viread. This cohort is expected to initiate in the second half of 2021. Antios will be responsible for the costs of adding this single cohort to its ongoing clinical trial. Arbutus will be responsible for the manufacture and supply of AB-729. The combination clinical trial cohort will include 10 subjects with chronic HBV infection assigned 8:2 to active drug (ATI-2173+AB-729) or matching placebos. The active drug (ATI-2173+AB-729) or placebo will be administered in combination with 300 mg of Viread (equivalent to 245 mg of tenofovir disoproxil fumarate). ATI-2173 and Viread will be administered once a day for 90 days. AB-729 will be administered by subcutaneous injection at Day 28 and Day 90. Following this 90 day treatment period, subjects will be followed-up for safety and sustained antiviral responses for 6 additional months. Any subjects whose HBV DNA remains below the limit of quantification (BLQ) at 6 months of follow-up will have HBV DNA and virology samples collected every 3 months off therapy until a detectable HBV DNA level is confirmed, or until 18 months after the 6 months of follow-up, whichever comes first. AB-729 is an RNA interference (RNAi) therapeutic targeted to hepatocytes using Arbutus’ novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery. AB-729 inhibits viral replication and reduces all HBV antigens, including hepatitis B surface antigen in preclinical models. Reducing hepatitis B surface antigen is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. Based upon clinical data generated thus far in an ongoing single- and multi-dose Phase 1a/1b clinical trial, AB-729 has demonstrated positive safety and tolerability data and meaningful reductions in hepatitis B surface antigen. ATI-2173 is a novel, orally-administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) molecule designed to deliver the 5’-monophosphate of clevudine to the liver. This L-nucleoside’s active 5’-triphosphate has unique antiviral properties as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site of HBV polymerase resulting in potent HBV antiviral activity and extended off-treatment suppression of HBV DNA. ATI-2173 targets the liver, delivering high levels of the unique 5’- triphosphate while limiting systemic exposure to the parent L-nucleoside. ATI-2173 has the potential to become an integral part of a curative combination regimen for chronic hepatitis B.

Fundamental Summary

Arbutus Biopharma's recently released results from Q1 indicate that Arbutus Biopharma is performing reasonably well and on par with its peers. The company's growth, value, and income factors all individually appear positive and give support for optimism regarding the likelihood of continued positive performance. Therefore, they earned a total score of 71 out of 100 and a HOLD recommendation.

Arbutus Biopharma reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 12.58 million compared to USD 2.11 million a year ago. Net loss was USD 15.77 million compared to USD 16.38 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.21 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.21 a year ago.

Business Description

Arbutus Biopharma, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma in July 2015. Arbutus Biopharma is headquartered in Warminster, Pennsylvania.

Sector Overview

Arbutus Biopharma is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Arbutus Biopharma's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 236.9 15.8% 65
Liabilities 71.0 102.7% 86
Price to Book 2.4 -26.7% 55
Cash & Equivalents 81.3 -25.6% 48
Equity 165.8 -2.1% 61
EBITDA -64.7 6.8% 82
Total Revenues 21.5 95.3% 37
Parameter Value Change Score
Return on Equity -54.0 3.9% 53
Net Cashflow 1.9 -96.7% 92
Capital Expenditure -0.8 3.0% 80
Asset Turnover 0.1 74.1% 87
Free Cashflow -0.2 61.4% 93

* All values are TTM

The below chart reflects Arbutus Biopharma's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Arbutus Biopharma's peer average final assessment score stands on 62.0, Arbutus Biopharma's score is 71.

  •  ABUS
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 36 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 37 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 38 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 39 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 40 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 41 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Arbutus Biopharma's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Arbutus Biopharma's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 62.

Neutral 62
Close Price 2.61
52W Low 1.98
52W High 4.62
5D MA 2.76
50D MA 2.48
200D MA 3.26
MACD 0.07
RSI 7.84
STOCH 42.59

Balance Sheet Analysis

Arbutus Biopharma appears likely to maintain its strong balance sheet metrics and momentum going forward. Arbutus Biopharma is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 71.0, representing 102.7% change from the previous period. These liabilities changes appear balanced compared to their peers and project the message that management is capable and focused on balancing asset growth, resource allocation, and growing liabilities. Therefore, we rated their liabilities movement with a score of 86. Also, The company's assets section could set high expectations for Arbutus Biopharma's future attractiveness, as they went to 236.9, which is a 15.8% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. The company's asset component, therefore, received a grade of 65. That said, one metric, Cash & Equivalents, stood out as particularly concerning. Arbutus Biopharma's management did a relatively poor job managing cash and cash equivalents, which now sit at 81.3 and represents a -25.6% change from the last reporting period. This performance is significantly less impressive than its peers and competitors. Consequently, their cash and cash equivalents movement received a grade of 48. Because its management is doing an excellent job managing these critical metrics, the balance sheet was given a score of 60.

Parameter Value Change Score
Assets 236.9 15.8% 65
Liabilities 71.0 102.7% 86
Price to Book 2.4 -26.7% 55
Cash & Equivalents 81.3 -25.6% 48
Equity 165.8 -2.1% 61
* All values are TTM

The below chart describes Arbutus Biopharma's performance as reflected on its balance sheet with respect to its peers. While Arbutus Biopharma received a balance sheet score of 60, the average of its peers stands on 63.0.

  •  ABUS
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 36 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 37 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 38 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 39 1
Geron Corporation 566.2M 69 72 37 59 62 60 40 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 41 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

EBITDA and Return Factors stand out as the most significant drivers of Arbutus Biopharma's income statement's strength. Arbutus Biopharma's management was effective in improving its EBIDTA, which now sits at -64.7 and represents a 6.8% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its EBITDA component earned a score of 82. Also, Arbutus Biopharma's reported return on equity (ROE) ratio was -54.0, representing a change of 3.9%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 53. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Arbutus Biopharma reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 21.5 and represented 95.3% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. Its revenue efficiency, therefore, received a grade of 37. Therefore, it received a score of 67.

Parameter Value Change Score
EBITDA -64.7 6.8% 82
Total Revenues 21.5 95.3% 37
Return on Equity -54.0 3.9% 53
* All values are TTM

The below chart describes Arbutus Biopharma's performance as reflected on its income statement with respect to its peers. While Arbutus Biopharma received a income statement score of 67 , the average of its peers stands on 64.0.

  •  ABUS
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 36 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 37 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 38 1
AnaptysBio, Inc. 586.3M 97 50 77 68 39 1
Geron Corporation 566.2M 89 67 73 78 40 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 41 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Arbutus Biopharma appears likely to maintain its strong cash flow metrics and momentum going forward. Arbutus Biopharma did a great job related to free cash flow this period, which stood at -0.2, representing a 61.4% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. Therefore, its free cash flow movement earned a score of 93. Also, Arbutus Biopharma's management was effective in improving their net cash flow, which now sits at 1.9 and represents a -96.7% change from the previous report. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. Hence, its net cash flow earned a score of 92. At the same time, one critical cash flow metric, Capital Expenditure, was notably weak. Arbutus Biopharma's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -0.8, which represents a 3.0% change from the last period. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Therefore, their CapEx movement component earned a score of 80. Because the company's management is doing an excellent job managing these critical metrics, the cash flow was given a score of 95.

Parameter Value Change Score
Net Cashflow 1.9 -96.7% 92
Capital Expenditure -0.8 3.0% 80
Asset Turnover 0.1 74.1% 87
Free Cashflow -0.2 61.4% 93
* All values are TTM

The below chart describes Arbutus Biopharma's performance as reflected on its cash flow with respect to its peers. While Arbutus Biopharma received a cash flow score of 95, the average of its peers stands on 69.0.

  •  ABUS
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 36 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 37 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 38 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 39 1
Geron Corporation 566.2M 78 68 49 81 77 40 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 41 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.